For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.
Borgoni, S., Sofyali, E., Soleimani, M., Wilhelm, H., Müller-Decker, K., Will, R., Noronha, A., Beumers, L., Verschure, P. J., Yarden, Y., Magnani, L., van Kampen, A. H. C., Moerland, P. D., & Wiemann, S. (2020). Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. Cancers, 12(10), [2918]. https://doi.org/10.3390/cancers12102918[details]
Soleimani Dodaran, M., Borgoni, S., Sofyali, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & van Kampen, A. H. C. (2020). Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer. BMC Cancer, 20, [676]. https://doi.org/10.1186/s12885-020-07100-z[details]
Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D. & Van Kampen, A. H. C. (2020). Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. Springer Nature. https://doi.org/10.6084/m9.figshare.c.5067306.v1
2020
Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D. & Van Kampen, A. H. C. (2020). Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. Springer Nature. https://doi.org/10.6084/m9.figshare.c.5067306.v1
The UvA uses cookies to ensure the basic functionality of the site and for statistical and optimisation purposes. Cookies are also placed to display third-party content and for marketing purposes. Click 'Accept all cookies' to consent to the placement of all cookies, or choose 'Decline' to only accept functional and analytical cookies. Also read the UvA Privacy statement.